

# Barry Greenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5556905/publications.pdf>

Version: 2024-02-01

85  
papers

5,578  
citations

159358

30  
h-index

79541

73  
g-index

86  
all docs

86  
docs citations

86  
times ranked

6498  
citing authors

#	ARTICLE	IF	CITATIONS
1	Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID). <i>Circulation</i> , 2011, 124, 304-313.	1.6	665
2	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e1054-e1091.	1.6	417
3	Effects of Long-term Enalapril Therapy on Cardiac Structure and Function in Patients With Left Ventricular Dysfunction. <i>Circulation</i> , 1995, 91, 2573-2581.	1.6	402
4	Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	383
5	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	6.3	373
6	Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. <i>American Heart Journal</i> , 2004, 148, 43-51.	1.2	308
7	Long-Term Effects of AAV1/SERCA2a Gene Transfer in Patients With Severe Heart Failure. <i>Circulation Research</i> , 2014, 114, 101-108.	2.0	271
8	Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 1994, 23, 1410-1420.	1.2	207
9	Design of a Phase 1/2 Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 355-367.	0.7	194
10	Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. <i>American Journal of Cardiology</i> , 1977, 40, 794-801.	0.7	179
11	Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 299-311.	1.2	148
12	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17058.	18.1	136
13	Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry. <i>Journal of the American College of Cardiology</i> , 1993, 22, A146-A153.	1.2	133
14	Improving risk prediction in heart failure using machine learning. <i>European Journal of Heart Failure</i> , 2020, 22, 139-147.	2.9	132
15	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 254-263.	1.2	124
16	Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 84-92.	1.9	123
17	Primary Results of the HABIT Trial (Heart Failure Assessment With BNP in the Home). <i>Journal of the American College of Cardiology</i> , 2013, 61, 1726-1735.	1.2	89
18	Role of Aldosterone Blockade for Treatment of Heart Failure and Post-acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 97, 34-40.	0.7	80

#	ARTICLE	IF	CITATIONS
19	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the <sc>COMMANDER HF</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 735-742.	2.9	73
20	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019, 40, 3593-3602.	1.0	69
21	Effects of Multiple Oral Doses of an A1Adenosine Antagonist, BG9928, in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 600-606.	1.2	66
22	Danon disease: Gender differences in presentation and outcomes. <i>International Journal of Cardiology</i> , 2019, 286, 92-98.	0.8	61
23	Targeting the ACE2&#x2013;Ang-(1&#x2013;7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 542-547.	0.9	58
24	Heart failure around the world. <i>European Journal of Heart Failure</i> , 2019, 21, 1187-1196.	2.9	56
25	Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. <i>Circulation Research</i> , 2019, 125, 265-281.	2.0	54
26	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. <i>JAMA Cardiology</i> , 2019, 4, 515.	3.0	51
27	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	1.9	44
28	The Impact of Substance Abuse on Heart Failure Hospitalizations. <i>American Journal of Medicine</i> , 2020, 133, 207-213.e1.	0.6	44
29	Acute Decompensated Heart Failure. <i>Circulation Journal</i> , 2012, 76, 532-543.	0.7	41
30	Prognosis of Stage A or B Heart Failure Patients With Elevated B-type Natriuretic Peptide Levels. <i>Journal of Cardiac Failure</i> , 2010, 16, 93-98.	0.7	34
31	Clinical Characteristics and Outcomes of Patients With Heart Failure and Methamphetamine Abuse. <i>Journal of Cardiac Failure</i> , 2020, 26, 202-209.	0.7	30
32	Novel Therapies for Heart Failure&#x2013; Where Do They Stand? &#x201c;. <i>Circulation Journal</i> , 2016, 80, 1882-1891.	0.7	24
33	Gene therapy for heart failure. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 216-222.	2.3	22
34	Contemporary Treatment of Acute Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 367-378.	1.6	21
35	How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF) Tj ETQq1 1 0.784314 rgBT21 Overload	0.7	20
36	Gene therapy for heart failure. <i>Journal of Cardiology</i> , 2015, 66, 195-200.	0.8	20

#	ARTICLE	IF	CITATIONS
37	A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 995-999.	2.9	20
38	Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?. <i>European Journal of Heart Failure</i> , 2003, 5, 13-21.	2.9	19
39	Heart Failure Preserved Ejection Fraction With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2828-2830.	1.2	19
40	Viral genome search in myocardium of patients with fulminant myocarditis. <i>European Journal of Heart Failure</i> , 2020, 22, 1277-1280.	2.9	19
41	Methamphetamine-associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities. <i>Journal of the American Heart Association</i> , 2021, 10, e018370.	1.6	19
42	Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1027.	3.0	18
43	Prognostic Value of Global Longitudinal Strain in Patients With Heart Failure With Improved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 27-37.	1.9	18
44	Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. <i>Clinical Cardiology</i> , 2019, 42, 277-284.	0.7	15
45	Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure. <i>International Journal of Heart Failure</i> , 2020, 2, 73.	0.9	15
46	The collagen receptor, discoidin domain receptor 2, functions in Gli1-positive skeletal progenitors and chondrocytes to control bone development. <i>Bone Research</i> , 2022, 10, 11.	5.4	15
47	A Case Series of Biventricular Circulatory Support Using Two Ventricular Assist Devices: A Novel Operative Approach. <i>Annals of Thoracic Surgery</i> , 2015, 100, e75-e77.	0.7	14
48	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	1.9	14
49	All Patients With Heart Failure and Intraventricular Conduction Defect or Dyssynchrony Should Not Receive Cardiac Resynchronization Therapy. <i>Circulation</i> , 2006, 114, 2685-2691.	1.6	13
50	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 648-656.	2.9	13
51	Identification of intracellular proteins and signaling pathways in human endothelial cells regulated by angiotensin-(1-7). <i>Journal of Proteomics</i> , 2016, 130, 129-139.	1.2	11
52	Treatment of Heart Failure: State of the Art and Prospectives. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S59-S63.	0.8	10
53	Anticoagulation Therapy and NOACs in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 515-535.	0.9	10
54	Atrial Arrhythmias and Extensive Left Atrial Fibrosis as the Initial Presentation of MYH7 Gene Mutation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1488-1490.	1.3	10

#	ARTICLE	IF	CITATIONS
55	Mineralocorticoid receptor antagonist use following heart failure hospitalization. ESC Heart Failure, 2020, 7, 482-492.	1.4	10
56	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF <sup>2</sup> study. European Journal of Heart Failure, 2021, 23, 58-67.	2.9	10
57	Classifying Heart Failure in the 21st Century. JACC: Heart Failure, 2021, 9, 771-773.	1.9	10
58	Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations. European Journal of Heart Failure, 2022, 24, 1418-1426.	2.9	10
59	Contemporary approach to treating heart failure. Trends in Cardiovascular Medicine, 2020, 30, 507-518.	2.3	9
60	Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation. Heart, 2021, 107, 741-747.	1.2	9
61	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173.	0.7	9
62	Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement. European Journal of Heart Failure, 2018, 20, 1536-1539.	2.9	8
63	Outcome of patients on heart transplant list treated with a continuous-flow left ventricular assist device: Insights from the Trans-Atlantic registry on VAd and Transplant (TRAVIATA). International Journal of Cardiology, 2021, 324, 122-130.	0.8	8
64	Predictors of Clinical Outcomes in Patients Given Carvedilol for Heart Failure. American Journal of Cardiology, 2006, 98, 1480-1484.	0.7	7
65	Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy. Current Heart Failure Reports, 2016, 13, 172-180.	1.3	6
66	Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211.	1.9	6
67	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, 2022, 111, 50-59.	1.5	6
68	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563.	1.5	5
69	Low mortality in SARS-CoV-2 infected heart transplant recipients at a single center. Clinical Transplantation, 2022, 36, .	0.8	5
70	Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or Metoprolol European Trial. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 1, S10-7.	0.5	5
71	Molecular Imaging of the Remodeling Heart: The Next Step Forward. JACC: Cardiovascular Imaging, 2008, 1, 363-365.	2.3	4
72	Further intracellular proteins and signaling pathways regulated by angiotensin-(1-7) in human endothelial cells. Data in Brief, 2017, 10, 354-363.	0.5	2

#	ARTICLE	IF	CITATIONS
73	Jumping down the rabbit hole: unravelling the right ventricle in heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1672-1674.	2.9	2
74	Gene therapy for heart failure: time to go back to the drawing board. <i>European Journal of Heart Failure</i> , 2017, 19, 1542-1544.	2.9	2
75	Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them. <i>European Journal of Heart Failure</i> , 2018, 20, 1335-1337.	2.9	2
76	Considering the gender gap in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 12-15.	2.9	2
77	Stand [Up] and Stand by for New Strategies for Treating Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 158-160.	1.9	2
78	Update on renin-angiotensin-aldosterone blockade in heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 455-466.	0.4	1
79	Managing hyponatremia in patients with heart failure. <i>Journal of Hospital Medicine</i> , 2010, 5, S33-9.	0.7	1
80	Implantable cardioverter-defibrillator therapy in patients with left ventricular assist devices: a shocking tale of survival. <i>European Journal of Heart Failure</i> , 2020, 22, 29-31.	2.9	1
81	Machine Learning Applications in Heart Failure Disease Management: Hype or Hope?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	1
82	Defining the Obvious: Maybe It Is Not So Easy —. <i>JACC: Heart Failure</i> , 2016, 4, 756-758.	1.9	0
83	NP Lowering in HFrEF. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1218-1219.	1.2	0
84	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. <i>Heart Failure Reviews</i> , 2021, 26, 255-262.	1.7	0
85	Reply to: “Worsening renal function after diuresis among heart failure patients with preserved ejection fraction: a dilemma to heart failure management”. <i>European Journal of Heart Failure</i> , 2021, 23, 495-495.	2.9	0